ShahMPerazellaMA.AKI in multiple myeloma: paraproteins, metabolic disturbances, and drug toxicity. J Onco-Nephrol2017; 1(3): 188–197.
2.
StokesMBValeriAMHerlitzL, et al. Light chain proximal tubulopathy: clinical and pathologic characteristics in the modern treatment era. J Am Soc Nephrol2016; 27(5): 1555–1565.
3.
LeboulleuxMLelongtBMougenotB, et al. Protease resistance and binding of Ig light chains in myeloma-associated tubulopathies. Kidney Int1995; 48(1): 72–79.
4.
KorbetSMSchwartzMM.Multiple myeloma. J Am Soc Nephrol2006; 17(9): 2533–2545.
5.
YadavPCookMCockwellP.Current trends of renal impairment in multiple myeloma. Kidney Dis2016; 1(4): 241–257.
